文献速递细菌感染、耐药与抗菌药物结核与非结核分枝杆菌

全基因组测序预测细菌药敏:EUCAST 2025年更新

The role of whole genome sequencing in antimicrobial susceptibility prediction of bacteria: 2025 update from the European Committee on Antimicrobial Susceptibility Testing Subcommittee.
PubMed 文献 · Clin Microbiol Infect · 2026-05-15

EUCAST 2024年成立特设小组,按菌种综述文献评估全基因组测序药敏预测(WGS-ASP)的现状与局限,覆盖肠杆菌目、铜绿假单胞菌、结核分枝杆菌等及宏基因组与AI进展。结论认为WGS-ASP在区分野生型与非野生型、敏感与耐药株方面证据增加,尤其对结核分枝杆菌及临床折点与ECOFF一致时;但作为临床决策工具仍存挑战,需表型基因型联合监测、统一解释框架与外部质评。

要点

  • WGS-ASP在区分野生型与非野生型、敏感与耐药株方面证据增加,尤其对结核分枝杆菌。
  • 临床折点与ECOFF一致时,WGS-ASP预测表现更受支持。
  • 作为临床决策工具前仍需统一解释框架、 harmonized生物信息工具与外部质评。

核心结论

  • WGS-ASP取得显著进展,尤其对结核分枝杆菌及临床折点与ECOFF一致时,但尚不足以作为临床决策工具。
  • 需整合表型与基因型监测、统一解释框架与外部质评以推进临床应用。

研究设计与样本

  • EUCAST 2024年成立特设小组,按菌种综述文献评估WGS-ASP的潜力与局限。
  • 综述菌种包括肠杆菌目、铜绿假单胞菌、鲍曼不动杆菌、淋病奈瑟菌、金黄色葡萄球菌、肺炎链球菌、艰难梭菌、结核分枝杆菌,并扩展至肠球菌、流感嗜血杆菌和脆弱拟杆菌。

主要发现

  • 自2017年EUCAST报告以来,WGS、生物信息工具、机器学习/人工智能、数据库与预测方法大幅扩展,耐药机制知识增加。
  • WGS-ASP区分野生型与非野生型、敏感与耐药株的证据增加,尤其对结核分枝杆菌及临床折点与ECOFF一致时。

临床怎么用

  • 当前WGS-ASP不宜替代表型药敏试验作为临床决策依据,需继续依赖参考方法表型药敏。
  • 应用WGS-ASP需确保数据集反映目标人群并涵盖完整药敏谱,采用统一解释框架与 harmonized生物信息工具。
  • 需建立稳健的外部质量评估方案进行临床验证,并评估成本与周转时间及特定场景的成本效益。

局限性

  • 复杂耐药机制与新型抗菌药物的证据基础仍需表型基因型联合监测加强。
  • 需比较评估同时考虑ECOFF与临床折点,且分析依赖参考方法表型药敏与高质量基因组数据。
  • 统一解释框架、 harmonized生物信息工具与外部质评尚未成熟,成本与周转时间仍需改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

SCOPE: The 2017 European Committee on Antimicrobial Susceptibility Testing (EUCAST) subcommittee report on the role of whole genome sequencing (WGS) in antimicrobial susceptibility testing (AST) concluded that WGS antimicrobial susceptibility prediction (WGS-ASP) was not a sufficiently robust alternative to AST to guide clinical decision making at that stage and that more evidence was required [1]. Since then, the use of WGS, bioinformatic tools, machine learning (ML)/artificial intelligence (AI), databases, and prediction approaches has greatly expanded, along with an increased knowledge of resistance mechanisms and their contribution to antimicrobial susceptibility. In response, a new EUCAST ad hoc subcommittee was established in 2024 to review the literature, with the aim of assessing the current potential and limitations of WGS-ASP. METHODS: As in the previous report, the subcommittee reviewed the literature on a 'by organism' basis but expanded the list to also include enterococci, Haemophilus influenzae, and Bacteroides fragilis in addition to those already included in the first version: Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, Neisseria gonorrhoeae, Staphylococcus aureus, Streptococcus pneumoniae, Clostridioides difficile, and Mycobacterium tuberculosis. Additional sections were included to cover advances in metagenomics, other omics technologies and ML/AI. The full report was compiled and reviewed by all subcommittee members before public consultation in November 2025. CONCLUSIONS AND RECOMMENDATIONS: Significant progress has been achieved in WGS-ASP, with growing evidence supporting its ability to distinguish wild-type from non-wild-type isolates and, consequently, susceptible from resistant strains, particularly for M. tuberculosis and when clinical breakpoints align with the epidemiological cut-off (ECOFF). Despite these advances, important challenges remain before WGS-ASP can be adopted as a clinical decision-making tool. Addressing these gaps will require integrated phenotypic and genotypic surveillance to strengthen the evidence base for complex resistance mechanisms and newer antimicrobial agents, alongside comparative assessments that consider both ECOFF and clinical breakpoints. The analyses will require reference method phenotypic AST and high-quality genomic data. It is critical to ensure that datasets reflect the target populations and encompass the full spectrum of antimicrobial susceptibility, while developing unified interpretation frameworks and harmonized bioinformatics tools to standardize outputs. Robust external quality assessment schemes will be essential for clinical validation, and emerging technologies such as AI and ML offer promising avenues to enhance predictive accuracy. Finally, improvements in cost and turnaround time, coupled with evaluations of setting-specific cost-effectiveness, will be key to enabling practical implementation of WGS-ASP.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Samuelsen Ø, López-Causapé C, Aarestrup FM, et al. The role of whole genome sequencing in antimicrobial susceptibility prediction of bacteria: 2025 update from the European Committee on Antimicrobial Susceptibility Testing Subcommittee. Clin Microbiol Infect. 2026. PMID: 42142806. doi:10.1016/j.cmi.2026.05.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。